StaceyMSteinMD
Oncology • New Brunswick, NJCancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer
Associate Professor of Medicine, Rutgers Cancer Institute, System Leader Med Onc Hepatobiliary Cancer RWJB Network
Dr. Stein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany St
New Brunswick NJ
New Brunswick, NJ 08903
Summary
- Dr. Stacey Stein is a medical oncologist focused on treating patients with GI cancers. She is based in New Brunswick, NJ and completed a fellowship in Hematology and Medical Oncology at the NYU Grossman School of Medicine in 2010, having graduated from Rutgers Robert Wood Johnson Medical School in 2004. Dr. Stein has significant experience dealing with conditions such as liver cancer, biliary cancer, pancreatic cancer, colon cancer. A published author, her research covers a range of cancer-related topics and her work has been cited in other publications. Dr. Stein has been involved in a number of clinical trials.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Rutgers Robert Wood Johnson Medical SchoolClass of 2004
Certifications & Licensure
CT State Medical License 2010 - 2025
NJ State Medical License 2024 - 2025
NY State Medical License 2007 - 2010- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
- Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Start of enrollment: 2017 Jan 01
Publications & Presentations
PubMed
- Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making.Rabea Sobirey, Nickolai Matuschewski, Moritz Gross, MingDe Lin, Tabea Kao
European Radiology. 2025-01-01 - Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms.Johannes Uhlig, James Nie, Joanna Gibson, Michael Cecchini, Stacey Stein
Scientific Reports. 2024-12-17 - 6 citationsPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.Michael Cecchini, Ronald R Salem, Marie Robert, Suzanne Czerniak, Ondrej Blaha
JAMA Oncology. 2024-08-01
Lectures
- Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer pat...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Dr. Stacey Stein and Dr. Neal Fischbach Appointed as Assistant Medical Directors at Yale Cancer Center Clinical Trials OfficeOctober 15th, 2021
New Investigation into PD-1 Blockade for Hepatocellular CarcinomaJanuary 10th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
